drugset
drugset / Trial / NCT03796260

A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants

NCT03796260 ↗

Phase 1 Completed 14 enrolled Genentech, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to investigate the relative bioavailability, safety, and tolerability of entrectinib capsule formulations F1 and F06 under fed conditions in healthy adult male and female participants.

Timeline

Start
2019-01-09
Primary completion
2019-02-04
Completion
2019-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Entrectinib Small molecule — Oral

Indications

No indication recorded.